DrugPatentWatch Database Preview
Cytogen Company Profile
Email this page to a colleague
» See Plans and PricingUS Patents for Cytogen
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 10,111,968 | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 10,590,182 | The Regents of the University of California (Oakland, CA) | 2035-02-24 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 7,826,889 | Spectrum Dynamics LLC (Orangeburg, NY) | 2020-08-21 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 8,420,081 | AbbVie, Inc. (North Chicago, IL) | 2027-11-30 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 8,722,019 | biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) | 2031-08-05 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 8,883,146 | AbbVie Inc. (North Chicago, IL) | 2027-11-30 | RX | search | |
| Cytogen | PROSTASCINT | capromab pendetide | VIAL; INTRAVENOUS | 103608 | 001 | 1996-10-28 | 8,962,804 | City of Hope (Duarte, CA) | 2030-10-08 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
